Is Pharma Right About the Need for a COVID-19 Booster Shot?

The intrinsic role of real-world data to help determine the necessity for booster shots as new COVID variants emerge

HVPCI notes a 5-point dip as COVID-19 restrictions tighten and telehealth fatigue sets in

November 24, 2020 - Philadelphia, PA - HealthVerity announced the most recent update to its HealthVerity Patient Confidence Index (HVPCI) and reported a national score of 93, a five-point decrease from the previous period in mid-October. With in-pers...

November 24, 2020 - Philadelphia, PA - HealthVerity announced the most recent update to its HealthVerity Patient Confidence Index (HVPCI) and reported a national score of 93, a five-point decrease from the previous period in mid-October. With in-person and telehealth visits tracked through the second week of November, this score highlights significant dips in patient and provider interactions across the vast majority of therapeutic areas. At the beginning of COVID-19 in the US, we noted a seesaw effect with low in-person visits and increased levels of telehealth usage. However, this seems to be taking a new shape with all visits reporting less volume over the previous month.

Blog Inset - 20-11-23 Patient Confidence Index Social – 3

The HVPCI represents a measure of physician visits undertaken by non-COVID-19 patients across 20 key therapeutic areas, highlighting a significant decline in visits since the pandemic took hold in the US at the beginning of March. The HVPCI is crucial as an expression of the confidence in patients to seek care for acute and chronic illnesses balanced with the risk of exposure to the coronavirus in a public setting. As coronavirus cases peak and eventually subside, this indicator will ultimately serve as an overall measure of US patient engagement between patients and their physicians.

COVID-19 93This period’s national score of 93 reflects a 5-point decrease from the previous index period, but more notably describes a very different patient story compared to the last report. In mid-October, many of the therapeutic areas tracked scores over the “normal” threshold of 100 and some even surpassed the rates of 2019. Although we do see a few specialties exceeding 100 this period, including GI & GUI (106), Infectious Disease (104) and Pediatrics (114), the majority are in decline since the last report. Infectious Disease reported a 12-point decrease in visits, for example, which contradicts the simultaneous rise in COVID-19 cases across the US.

Perhaps most concerning is the drastic downturn in visits within Preventive Med (89), reporting a 21-point decrease from last period. As cases rise and patient confidence in attending in-person doctors visits wane due to the concern of contracting the virus, we have to hope that precautionary measures for other disease areas don’t fall to the back burner.

Snapshot of specialties tracked by the HVPCI:

Specialty  HVPCI #1 Last period  This period Point change
Overall 68 98 93 -5
Cardiovascular 70 90 82 -8
Dermatology 46 91 82 -9
Endocrinology 62 95 87 -8
FP/GP 73 100 100 0
GI & GU 73 109 106 -3
Infectious Disease 90 116 104 -12
Oncology  78 88 86 -2
Pediatrics 68 116 114 -1
Preventative Med 78 110 89 -21
Rheumatology 64 94 89 -5


Conversely, telehealth visits remain consistently flat, accounting for about 8% of all visits across the US. The HVPCI reports that the 65+ age group continuously remains the largest user group of this service across all specialities (other than pediatrics and behavioral health), but as COVID-19 cases rise once again, telehealth accessibility has become a bit more complicated in recent weeks. According to NextGov and the Wall Street Journal, “Several big private insurers are pulling back some of their coverage of telehealth for non-COVID issues. Companies including UnitedHealthcare have already rolled back policies that waived co-pays and other fees for non-COVID-related appointments. Other plans such as Anthem BlueCross BlueShield have extended their coverage through the end of the year, but only the first two sessions are free for the consumer.”

Learn more about HealthVerity’s efforts to educate and inform on COVID-19 here.

Related Post:

The IPGE Platform: A transformational approach for the modern healthcare enterprise

In our latest HealthVerity LIVE webinar, we took an in-depth look at how the Identity, Privacy, Governance and Exchange ...

Enriching clinical trials with real-world data

COVID-19 urgently highlighted the need for real-time data, and with it, the need to tap into a wider variety of data sou...

Accurate, de-identified patient data: The key to a longitudinal patient journey

A data-rich longitudinal patient journey is key to research and development, commercialization and marketing in the worl...

Subscribe to the HealthVerity blog

Let's work together